Clinical Trial Update: A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating SRP-9005 for Limb-Girdle Muscular Dystrophy Type 2C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type 2c

Drugs mentioned

• SRP-9005

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Muscular Dystrophies, Limb-Girdle | Phase 3 | Status: WITHDRAWN